B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

NR5A1

MOLECULAR TARGET

nuclear receptor subfamily 5 group A member 1

UniProt: Q13285NCBI Gene: 251627 compounds

NR5A1 (nuclear receptor subfamily 5 group A member 1) is targeted by 27 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting NR5A1

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Cladribine1.393
2vinblastine sulfate1.393
3Progesterone1.102
4Gemfibrozil1.102
5Podophyllotoxin1.102
6Triiodothyronine1.102
7Methylene Blue0.691
8Resveratrol0.691
9Aldosterone0.691
10Methotrexate0.691
11Anisomycin0.691
12Azacitidine0.691
13Azacitidine0.691
14Bromodeoxyuridine0.691
15calycosin0.691
16Cilostazol0.691
17clofilium tosylate0.691
18cycloheximide0.691
19Digitoxigenin 3 beta,14-Dihydroxy-5 beta-card-20(22)enolide.0.691
20Digoxigenin 3 beta,12 beta,14-Trihydroxy-5 beta-card-20(22)-enolide.0.691
21Digoxin0.691
22dihydrorotenone0.691
23Ethidium0.691
24Lanatosides Glycosides from DIGITALIS lanata leaf. Lanatoside C has actions similar to DIGOXIN. Mixtures of lanatosides A, B, and C have also been used. (From Martindale,0.691
25Strophanthidin 3 beta,5,14-Trihydroxy-19-oxo-5 beta-card-20(22)-enolide.0.691
26Tubercidin0.691
27tyrphostin 90.691

About NR5A1 as a Drug Target

NR5A1 (nuclear receptor subfamily 5 group A member 1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 27 compounds with documented NR5A1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

NR5A1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.